menu search

Jubilee metals ceo talks progress and prospects - icymi

In conversation with Thomas Warner from Proactive, Leon Coetzer, CEO of Jubilee Metals Group PLC (AIM:JLP, JSE:JBL, OTC:JUBPF), delved into the strat...

November 4, 2023, 6:38 am

Kefi gold and copper: a comprehensive update on operational progress and market dynamics - icymi

In this interview, Thomas Warner from Proactive chats with Harry Anagnostaras-Adams, the executive chairman of KEFI Gold and Copper PLC (AIM:KEFI, OT...

November 4, 2023, 5:29 am

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Autolus therapeutics plc (autl) q3 2023 earnings call transcript

Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Company Participants Julia Wilson – Investor Re...

November 3, 2023, 10:05 pm

Update — upcoming christmas comedy from executive producers logan sekulow and sean hannity to premiere exclusively on rumble

Jingle Smells features an all-star cast, including John Schneider, Eric Roberts, Ben Davies, Jim Breuer, Victoria Jackson, Dylan Postl, James Storm, B...

November 3, 2023, 9:33 pm

Mobiv acquisition corp provides further update on planned business combination

Newark, DE, Nov. 03, 2023 (GLOBE NEWSWIRE) — Mobiv Acquisition Corp (the “Company” or “Mobiv”) announced that it intends to enter into a Loc...

November 3, 2023, 9:00 pm

Vida markets expands trading horizons: mt4 and mt5 access now available

The global brokerage firm Vida Markets is offering a dual access to the MT4 and MT5 platforms. This update...

November 3, 2023, 8:58 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

November 2023 letter to shareholders

VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) — Dear Shareholders, We write to provide an update...

November 3, 2023, 8:02 pm

Prime medicine reports third quarter 2023 financial results and provides business updates

— Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well...

November 3, 2023, 8:01 pm

Kineta reports third quarter 2023 financial results and provides corporate update

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in comb...

November 3, 2023, 8:01 pm

Update: korro bio and frequency therapeutics announce closing of merger and private placement of $117 million

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fu...

November 3, 2023, 7:31 pm

Actinium pharmaceuticals: the trickle down continues, and i maintain a buy

Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. Th...

November 3, 2023, 6:08 pm

P3 health partners schedules third-quarter 2023 earnings release and conference call

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led populat...

November 3, 2023, 4:15 pm

Bausch health (bhc) q3 earnings & sales beat, '23 view updated

Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth....

November 3, 2023, 3:47 pm

Beyond meat (bynd) announces preliminary results for q3

Beyond Meat's (BYND) third-quarter 2023 preliminary results suggest revenue declines of 9% and 26.5% on a year-over-year and sequential basis, respect...

November 3, 2023, 1:32 pm


Search within

Pages Search Results: